S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Arvinas Stock Forecast, Price & News

+0.96 (+1.35 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $72.04
50-Day Range
MA: $80.46
52-Week Range
Now: $72.04
Volume569,544 shs
Average Volume521,529 shs
Market Capitalization$3.52 billion
P/E RatioN/A
Dividend YieldN/A
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Arvinas logo


Arvinas: Q4 Earnings Insights - Yahoo Finance
March 2, 2021 |  finance.yahoo.com
Arvinas: Q4 Earnings Insights
March 1, 2021 |  finance.yahoo.com
Arvinas: Q4 Earnings Insights - Benzinga
March 1, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ARVN
Year FoundedN/A



Sales & Book Value

Annual Sales$42.98 million
Book Value$6.72 per share


Net Income$-70,290,000.00
Net Margins-403.77%


Market Cap$3.52 billion
Next Earnings Date4/27/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.88 out of 5 stars

Medical Sector

120th out of 1,972 stocks

Pharmaceutical Preparations Industry

47th out of 772 stocks

Analyst Opinion: 4.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
+0.96 (+1.35 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARVN News and Ratings via Email

Sign-up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Arvinas (NASDAQ:ARVN) Frequently Asked Questions

Is Arvinas a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arvinas stock.
View analyst ratings for Arvinas
or view top-rated stocks.

What stocks does MarketBeat like better than Arvinas?

Wall Street analysts have given Arvinas a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arvinas wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Arvinas' next earnings date?

Arvinas is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for Arvinas

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) issued its quarterly earnings data on Sunday, February, 28th. The company reported ($0.99) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.78) by $0.21. Arvinas had a negative trailing twelve-month return on equity of 46.99% and a negative net margin of 403.77%.
View Arvinas' earnings history

How has Arvinas' stock been impacted by Coronavirus?

Arvinas' stock was trading at $44.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARVN stock has increased by 63.5% and is now trading at $72.04.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ARVN?

9 equities research analysts have issued 12-month price objectives for Arvinas' shares. Their forecasts range from $45.00 to $129.00. On average, they expect Arvinas' stock price to reach $105.91 in the next year. This suggests a possible upside of 47.0% from the stock's current price.
View analysts' price targets for Arvinas
or view top-rated stocks among Wall Street analysts.

Who are Arvinas' key executives?

Arvinas' management team includes the following people:
  • Dr. John G. Houston Ph.D., CEO, Pres & Director (Age 61, Pay $949.5k)
  • Mr. Sean A. Cassidy CPA, CFO & Treasurer (Age 51, Pay $551.9k)
  • Dr. Ronald A. Peck, Chief Medical Officer
  • Dr. Craig M. Crews, Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
  • Dr. Ian Taylor, Chief Scientific Officer (Age 58)
  • Mr. Matthew Batters, VP of Bus. Devel. & Counsel (Age 45)
  • Dr. Robert Kleinfield, Chief Devel. Officer
  • Dr. Randy Teel, VP of Corp. Devel. (Age 42)
  • Mr. Steve Weiss, VP of HR (Age 52)
  • Ms. Marcia Dougan Moore, Sr. VP of Strategic Operations (Age 55)

Who are some of Arvinas' key competitors?

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Canaan Partners IX LLC (7.41%), BlackRock Inc. (5.82%), Price T Rowe Associates Inc. MD (4.64%), Avidity Partners Management LP (3.69%), JPMorgan Chase & Co. (3.33%) and Northern Trust Corp (0.81%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am.
View institutional ownership trends for Arvinas

Which institutional investors are selling Arvinas stock?

ARVN stock was sold by a variety of institutional investors in the last quarter, including Canaan Partners IX LLC, UBS Asset Management Americas Inc., SG Americas Securities LLC, Morgan Stanley, Squarepoint Ops LLC, Engineers Gate Manager LP, Candriam Luxembourg S.C.A., and First Trust Advisors LP. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Ian Taylor, John G Houston, Ronald Peck, and Sean A Cassidy.
View insider buying and selling activity for Arvinas
or view top insider-selling stocks.

Which institutional investors are buying Arvinas stock?

ARVN stock was purchased by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, BlackRock Inc., JPMorgan Chase & Co., Avidity Partners Management LP, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Caas Capital Management LP, and Renaissance Technologies LLC. Company insiders that have bought Arvinas stock in the last two years include Briggs Morrison, Ian Taylor, Liam Ratcliffe, and Timothy M Shannon.
View insider buying and selling activity for Arvinas
or or view top insider-buying stocks.

How do I buy shares of Arvinas?

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $72.04.

How much money does Arvinas make?

Arvinas has a market capitalization of $3.52 billion and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis.

How many employees does Arvinas have?

Arvinas employs 133 workers across the globe.

What is Arvinas' official website?

The official website for Arvinas is www.arvinas.com.

Where are Arvinas' headquarters?

Arvinas is headquartered at 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.